



Global Health L i m i t e d

August 8, 2024

Ref:- GH/2024-25/EXCH/43

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('GHL/Company') at its meeting held today i.e. *Thursday, August 8, 2024*, has *inter alia*, approved:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2024 ('Results');

The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiook & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Exhibit-I** pursuant to Regulation 33 of the Listing Regulations.

2. Notice of 20th Annual General Meeting of the Company to be held on *Thursday, September 19, 2024 at 12:00 Noon* through Video Conferencing/Other Audio Video Means ('VC/OAVM') Facility.
3. Construction of service apartments/guest house as part of "Medanta-The Medicity" campus which will also include necessary facilities for the international and domestic patients and their families.

The details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure A** respectively.

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.


The meeting of the Board of Directors commenced at 2.00 P.M. and concluded at 3:50 P.M

Thanking You,

For Global Health Limited


Rahul Ranjan
Company Secretary & Compliance Officer
M. No: A17035
Encl. a/a






Global Health L i m i t e d

Annexure A

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Name of the Service/Product	The construction of service apartments and a guest house as part of the "Medanta-The Medicity" campus with an estimated capex of Rs 250 Cr. This project aims to enhance the Medicity campus in Gurgaon and cater to the growing demand from international patients, creating an integrated healthcare ecosystem. The new facilities will provide necessary amenities for both international and domestic patients and their families, enhancing their overall experience and supporting Medanta's commitment to comprehensive healthcare.
Date of Launch	To be decided upon completion of construction
Category of Service	Commercial
Name of the Country in which the service launched	Medanta-The Medicity, Sector 38, Gurugram, India.

Ranjit



Walker Chandiook & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') for the quarter ended 30 June 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker ChandioK &Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Tarun

Tarun Gupta

Partner

Membership No. 507892



UDIN: 24507892BKEIVV8009

Place: Gurugram

Date: 08 August 2024

Chartered Accountants

Global Health Limited
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2024

(₹ in millions, unless otherwise stated)

S No.	Particulars	Quarter ended			Year ended
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		(Unaudited)	(Audited) (Refer note 6)	(Unaudited)	(Audited)
	Income				
I	Revenue from operations	6,114.49	5,786.45	5,505.07	22,800.08
II	Other income	266.98	325.47	272.84	1,028.68
	Total income	6,381.47	6,111.92	5,777.91	23,828.76
	Expenses				
III	Cost of materials consumed	1,405.61	1,337.95	1,203.35	5,061.46
	Purchases of stock-in-trade	116.91	99.53	111.50	423.39
	Changes in inventories of stock-in-trade	(5.24)	(1.60)	(10.20)	(6.25)
	Employee benefits expense	1,575.01	1,491.67	1,458.64	5,910.62
	Finance costs	59.52	62.11	63.81	244.57
	Depreciation and amortisation expense	233.03	233.90	204.28	870.90
	Impairment losses on financial assets	36.03	107.81	63.41	277.32
	Retainers and consultants fee	653.57	600.28	547.29	2,332.12
	Other expenses	1,009.60	928.62	978.44	3,827.92
	Total expenses	5,084.04	4,860.27	4,620.52	18,942.05
IV	Profit before tax	1,297.43	1,251.65	1,157.39	4,886.71
V	Tax expenses				
	Current tax	321.47	342.26	345.50	1,383.40
	Tax pertaining to earlier years	-	-	-	12.35
	Deferred tax charge/(credit)	13.12	(12.97)	(50.23)	(117.95)
VI	Profit after tax	962.84	922.36	862.12	3,608.91
VII	Other comprehensive income				
	A (i) Items that will not be reclassified to statement of profit or loss	(25.38)	(0.89)	(28.58)	(14.91)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	6.39	0.22	7.19	3.75
	Total other comprehensive income	(18.99)	(0.67)	(21.39)	(11.16)
VIII	Total comprehensive income	943.85	921.69	840.73	3,597.75
IX	Paid-up equity share capital (face value of ₹ 2 each)	537.01	537.01	536.54	537.01
X	Reserves (other equity)				27,950.97
XI	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)				
	Basic (₹ per share)	3.58	3.43	3.21	13.44
	Diluted (₹ per share)	3.58	3.43	3.21	13.44

See accompanying notes to the standalone unaudited financial results



(This space has been intentionally left blank)



Global Health Limited

Notes to the unaudited standalone financial results:

- 1 The above standalone financial results for the quarter ended on 30 June 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 08 August 2024 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment. The Company is operating in India which constitutes a single geographical segment.
- 4 The Board of Directors of the Company at their meeting held on 21 March 2024 had approved the Scheme of Amalgamation ('Scheme') between Medanta Holdings Private Limited, wholly owned subsidiary, (Transferor Company) and the Company (Transferee Company) and their respective members and creditors under section 230 to 232 of the Act. The Company has filed the application with National Company Law Tribunal ('NCLT') on 06 May 2024. Pursuant to the NCLT order dated 12 June 2024, the Scheme has been approved in the meetings of the unsecured creditors and shareholders of the Company held on 03 August 2024. The Company will file the second motion application with NCLT for approval of the Scheme.
- 5 The Board of Directors of the Company, at their meeting held on 24 July 2024, have approved the acquisition of land parcel, on lease basis, situated at Mauje-Oshiwara, Jogeshwari, Mumbai, offered by Mumbai Housing and Area Development Authority (MHADA) under online e-tenders.
- 6 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures for the full financial year and the unaudited published year to date figures for 31 December 2023, which were subjected to limited review by the statutory auditors.
7. Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

Dr. Naresh Trehan
Chairman and Managing Director

Place : Gurugram
Date : 08 August 2024



60

Walker Chandiook & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Tarun Gupta

Partner

Membership No. 507892



UDIN: 24507892BKEIVW6973

Place: Gurugram

Date: 08 August 2024

Chartered Accountants

Walker ChandioK & Co LLP

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Medanta Holdings Private Limited	Wholly owned subsidiary
2	Global Health Patliputra Private Limited	Wholly owned subsidiary
3	GHL Pharma & Diagnostic Private Limited (Formerly known as Global Health Pharmaceuticals Private Limited)	Wholly owned subsidiary
4	GHL Hospital Limited (incorporated on 11 December 2023)	Subsidiary
5	Global Health Institute of Medical Sciences Foundation (incorporated on 30 March 2024)	Wholly owned subsidiary



Chartered Accountants

Global Health Limited
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2024

(₹ in millions, unless otherwise stated)

S. No.	Particulars	Quarter ended			Year ended
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		(Unaudited)	Audited (Refer note 6)	(Unaudited)	(Audited)
	Income				
I	Revenue from operations	8,610.77	8,086.31	7,795.80	32,751.11
II	Other income	219.27	274.22	149.19	746.64
	Total income	8,830.04	8,360.53	7,944.99	33,497.75
	Expenses				
III	Cost of materials consumed	1,876.05	1,765.17	1,645.17	6,876.86
	Purchases of stock-in-trade	230.97	175.65	182.98	739.68
	Changes in inventories of stock-in-trade	(18.38)	(3.41)	(14.44)	(22.94)
	Employee benefits expense	2,011.85	1,878.01	1,780.70	7,348.58
	Finance costs	179.79	182.29	179.16	739.13
	Depreciation and amortisation expense	466.18	454.53	403.83	1,727.28
	Impairment losses on financial assets	49.03	117.56	64.41	293.13
	Retainers and consultants fee	1,184.79	1,080.82	1,000.24	4,270.28
	Other expenses	1,413.24	1,279.04	1,292.52	5,254.76
	Total expenses	7,393.52	6,929.66	6,534.57	27,226.76
IV	Profit before tax	1,436.52	1,430.87	1,410.42	6,270.99
	Tax expenses				
	Current tax	364.21	391.95	419.18	1,777.38
	Tax pertaining to earlier years	-	-	-	12.35
	Deferred tax charge/(credit)	9.67	(234.55)	(28.86)	(299.34)
V	Profit after tax	1,062.64	1,273.47	1,020.10	4,780.60
	Other comprehensive income				
	(i) Items that will not be reclassified to statement of profit or loss	(27.10)	(0.07)	(31.43)	(12.69)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	6.83	(0.02)	7.35	3.31
VI	Total other comprehensive income	(20.27)	(0.09)	(24.08)	(9.38)
VII	Total comprehensive income	1,042.37	1,273.38	996.02	4,771.22
	Profit after tax attributable to:				
	(i) Owners of the Holding Company	1,062.86	1,273.81	1,020.10	4,781.94
	(ii) Non-controlling interests	(0.22)	(0.34)	-	(1.34)
	Other comprehensive income attributable to:				
	(i) Owners of the Holding Company	(20.27)	(0.09)	(24.08)	(9.38)
	(ii) Non-controlling interests	-	-	-	-
	Total comprehensive income attributable to:				
	(i) Owners of the Holding Company	1,042.59	1,273.72	996.02	4,772.56
	(ii) Non-controlling interests	(0.22)	(0.34)	-	(1.34)
VIII	Paid-up equity share capital (face value of ₹ 2 each)	537.01	537.01	536.54	537.01
IX	Reserves (other equity)				28,519.26
X	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)				
	Basic (₹ per share)	3.96	4.74	3.80	17.80
	Diluted (₹ per share)	3.96	4.74	3.80	17.80

See accompanying notes to the consolidated unaudited financial results



Global Health Limited

Notes to the unaudited consolidated financial results:

- 1 The above consolidated financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group') for the quarter ended 30 June 2024 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 08 August 2024 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Group's performance from a service perspective and has identified the Healthcare services as single business segment. The Group is operating in India which constitutes a single geographical segment.
- 4 The Board of Directors of the Holding Company at their meeting held on 21 March 2024 had approved the Scheme of Amalgamation ('Scheme') between Medanta Holdings Private Limited, wholly owned subsidiary, (Transferor Company) and the Holding Company (Transferee Company) and their respective members and creditors under section 230 to 232 of the Act. The Holding Company has filed the application with National Company Law Tribunal ('NCLT'), Delhi on 06 May 2024. Pursuant to the NCLT order dated 12 June 2024, the Scheme has been approved in the meetings of the unsecured creditors and shareholders of the Holding Company held on 03 August 2024. The Holding Company will file the second motion application with NCLT for approval of the Scheme.
- 5 The Board of Directors of the Holding Company, at their meeting held on 24 July 2024, have approved the acquisition of land parcel , on lease basis, situated at Mauje-Oshiwara, Jogeshwari, Mumbai, offered by Mumbai Housing and Area Development Authority (MHADA) under online e-tenders.
- 6 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures for the full financial year and the unaudited published year to date figures for 31 December 2023, which were subjected to limited review by the statutory auditors.
- 7 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

Dr. Naresh Trehan
Chairman and Managing Director

Place : Gurugram
Date : 08 August 2024

